Related Experiment Videos
Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders
M Romano1, P Viero, S Cortellazzo
1Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italia.
Abstract:
Mitogenic activity, measured as 3H-thymidine incorporation by NIH 3T3 cells, following stimulation with platelet-rich-plasma-derived serum (PRS), platelet-poor-plasma-derived serum and platelet extract was studied in 14 patients with myeloproliferative disorders (MPD) and 7 normal subjects. Reduced mitogenic activity was found in PRS and platelet extract of patients with MPD, as compared to controls. The average levels of platelet-derived growth factor (PDGF) equivalents were as follows: 16.3 +/- 7.2 pg/10(6) platelets in controls, 6.2 +/- 2.2 pg/10(6) (p less than 0.05) platelets in patients with polycythaemia vera, 1.8 +/- 0.4 pg/10(6) (p less than 0.01) platelets in patients with idiopathic myelofibrosis and 4.0 +/- 0.8 pg/10(6) (p less than 0.05) platelets in patients with essential thrombocythaemia (Dunnett test). A reduction of intraplatelet levels of beta-thromboglobulin, although not statistically significant, was found in the same patients. No apparent relation was found between the amount of PDGF equivalents and the degree of bone marrow fibrosis.
Insights
Patients with myeloproliferative disorders (MPD) show reduced platelet-derived growth factor (PDGF) levels and mitogenic activity. This finding suggests a potential role for PDGF in MPD pathogenesis.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Myeloproliferative disorders (MPD) are a group of clonal hematopoietic stem cell diseases.
- Platelet-derived growth factor (PDGF) plays a role in cell growth and proliferation.
- Alterations in PDGF signaling may contribute to MPD development.
Purpose of the Study:
- To investigate the mitogenic activity and PDGF levels in patients with MPD.
- To compare these parameters between MPD patients and healthy controls.
Main Methods:
- Assessed mitogenic activity using 3H-thymidine incorporation in NIH 3T3 cells.
- Stimulated cells with platelet-rich plasma-derived serum (PRS) and platelet extract.
- Quantified PDGF equivalents in platelets from MPD patients and controls.
Main Results:
- MPD patients exhibited significantly reduced mitogenic activity in PRS and platelet extract compared to controls.
- Average PDGF levels were lower in polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia patients.
- A non-significant reduction in intraplatelet beta-thromboglobulin was observed in MPD patients.
Conclusions:
- Reduced PDGF levels and mitogenic activity in MPD suggest impaired platelet growth factor function.
- These findings may have implications for understanding MPD pathogenesis.
- Further research is warranted to explore the therapeutic potential of targeting PDGF signaling in MPD.